RecruitingNCT06786936
IL-17 and depressive symptoms in psoriatic arthritis
About this title
Read the official source — NCT06786936Observational studyAges 18–74United KingdomDepression
Understand this study
Who could participate?
Listed age limits: 18 years to 74 years.
- Listed locations
- GlasgowSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: June 2, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- NHS Greater Glasgow and Clyde
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Drug
- Locations
- United Kingdom
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT06786936
- Official title
Show the full official title
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Glasgow
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NHS Greater Glasgow and Clyde.
Does this study involve medication?
Yes. The study involves medication, including Secukinumab, Bimekizumab, Ixekizumab and Placebo.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as recruiting.
